ArticleCureus2024
Emerging Trend of Central Precocious Puberty: A Retrospective Study of Cases Diagnosed Before and During the COVID-19 Pandemic in a Portuguese Tertiary-Level Hospital.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Back to normal? A retrospective study on stimulation test and endocrinological diagnosis before, during and after COVID-19 pandemics.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn light of the recent evidence suggesting an increase in idiopathic central precocious puberty (ICPP) during the COVID-19 pandemic, this study aimed to assess the incidence of newly diagnosed ICPP cases and compare differences in demographic, anthropometric, and clinical characteristics pre-pandemic and during the pandemic.
methodsWe conducted a retrospective study at a national reference pediatric endocrinology unit in Portugal to evaluate the proportion of referrals for precocious puberty (PP) and, within this group, the number of ICPP cases diagnosed before (group 1: January 2018 to March 2020) and during the pandemic (group 2: April 2020 to June 2022). Additionally, we compared the demographic, anthropometric, and clinical characteristics of ICPP patients between the two groups.
resultsOut of 258 patients referred for PP, 20 were diagnosed with ICPP (19 girls and one boy). Sixteen cases were diagnosed during the pandemic, marking a significant increase (16 vs. 4, p = 0.023), especially among girls. Additionally, thelarche onset occurred earlier during the pandemic (6.9 vs. 7.3, decimal age (DA) in years, p = 0.035). Despite pandemic challenges, a prompt medical response was observed, with a shorter time from first visit to treatment (DA at the onset of treatment - DA at first visit: 0.19 vs. 0.79 years; p = 0.015). No other parameters showed significant differences. Referrals for PP during the pandemic were not significantly higher than pre-pandemic (144 of 904 vs. 114 of 758, p > 0.05).
conclusionThis study revealed a significant four-fold increase in the diagnosis of ICPP during the pandemic, particularly among girls. Furthermore, in the pandemic group, thelarche onset was earlier, raising the question of whether increased parental presence at home contributed to heightened awareness of pubertal changes. Despite the challenges posed by the pandemic in terms of referrals and follow-up, these results point to efficient work that led to prompt treatment initiation without delays, unlike in other pathologies, as mainly observed in adults. Surprisingly, no significant increase in body mass index was observed, suggesting that other factors may be involved. To substantiate these findings and uncover additional potential contributing factors for the development of ICPP, a more extensive research effort is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.